Marni Kottle - Biomarin Pharmaceutical Executive Officer
| BMRN Stock | USD 65.42 0.54 0.83% |
Executive
Marni Kottle is Executive Officer of Biomarin Pharmaceutical
| Address | 770 Lindaro Street, San Rafael, CA, United States, 94901 |
| Phone | 415 506 6700 |
| Web | https://www.biomarin.com |
Biomarin Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.03 % which means that it generated a profit of $0.03 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0625 %, meaning that it created $0.0625 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.04. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 29th of November 2024, Debt To Assets is likely to grow to 0.31, while Non Currrent Assets Other are likely to drop about 72.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tushar MD | Liquidia Technologies | 63 | |
| Kenneth Myszkowski | Arrowhead Pharmaceuticals | 58 | |
| Harp MBA | Vaxcyte | 51 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| Clive Patience | Agios Pharm | 60 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Russell Schundler | Liquidia Technologies | 49 | |
| Tram Bui | Halozyme Therapeutics | N/A | |
| Jeffrey JD | Exelixis | 55 | |
| Muthiah Manoharan | Alnylam Pharmaceuticals | 71 | |
| Hayley Soffer | Ionis Pharmaceuticals | N/A | |
| Mark Esq | Halozyme Therapeutics | N/A | |
| Cortney MBA | Halozyme Therapeutics | N/A | |
| Kevin Smyth | Bio Techne Corp | N/A | |
| Patrick MBA | Exelixis | 48 | |
| Christopher Taylor | Agios Pharm | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
Management Performance
| Return On Equity | 0.0625 | ||||
| Return On Asset | 0.03 |
Biomarin Pharmaceutical Leadership Team
Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Traci McCarty, Group Relations | ||
| Jonathan Day, Executive Science | ||
| George Davis, Chief VP | ||
| Brian CPA, CFO VP | ||
| Marni Kottle, Executive Officer | ||
| Humaira Serajuddin, Senior Officer | ||
| Brian Mueller, Chief Accounting Officer, Group VP and Controller | ||
| Philip Scalzo, VP Officer | ||
| Erin Burkhart, Group Officer | ||
| Greg Guyer, Executive Officer | ||
| Ganesh Vedantham, Senior Development | ||
| Kevin Eggan, Chief Development | ||
| Yen Wing, Vice Science | ||
| Amy Wireman, Executive Officer | ||
| Jeffrey Ajer, Executive Officer | ||
| Alexander Hardy, CEO President | ||
| MBA MBA, Chairman CEO | ||
| George JD, Chief VP | ||
| Brinda MD, Chief VP |
Biomarin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0625 | ||||
| Return On Asset | 0.03 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 12.14 B | ||||
| Shares Outstanding | 190.58 M | ||||
| Shares Owned By Insiders | 0.88 % | ||||
| Shares Owned By Institutions | 97.56 % | ||||
| Number Of Shares Shorted | 5.12 M | ||||
| Price To Earning | 220.73 X |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Biomarin Stock
| 0.62 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
Moving against Biomarin Stock
| 0.88 | BHC | Bausch Health Companies | PairCorr |
| 0.79 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.79 | GILD | Gilead Sciences | PairCorr |
| 0.73 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.59 | ESPR | Esperion Therapeutics | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.